Prostate cancer is now the most common nondermatological male malignancy and is the second most common cause of male cancer related death in the UK; approximately 1 in 14 men in the UK will be diagnosed with prostate cancer in their life-time.1 Prostate cancer is strongly associated with increasing age, with the mean age of onset being 72-74 years 2 and 96% cases occurring in men over 60 years.3 Cancer chemoprevention can be thought to include reversal and delay of carcinogenesis, in addition to prevention. The high incidence and late age of onset make prostate cancer an ideal target for chemoprevention strategies. Even a modest delay in carcinogenesis would significantly reduce the incidence of the disease. This article reviews completed and on-going phase III clinical trials, of various compounds proposed as prostate cancer preventive agents. It will also discuss the future of research in this area. Prostate cancer is an excellent target for chemoprevention strategies; given its late age of onset, any delay in carcinogenesis would lead to a reduction in its incidence. This article reviews all the completed and on-going phase III trials in prostate cancer chemoprevention.
Patients and Methods
Platin im Getriebe: Dynamische 1H‐NMR‐spektroskopische Untersuchungen an Platin(II)‐Organometallverbindungen zeigen, dass die Rotation um die Pt‐P‐Bindung und der Wechsel des Phenanthrolin‐Liganden zwischen zwei nichtäquivalenten Positionen synchron verlaufen. Die dynamischen Eigenschaften des Systems, das einem mechanischen Räderwerk im Molekülformat entspricht (siehe Bild; C grau, N blau, O rot, P violett), sind durch geringe Strukturmodifizierungen einstellbar.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.